Statistical appproaches to handling uncertainty in health economic evaluation

European Journal of Gastroenterology and Hepatology

Volumn 16, Issue 6, 2004, Pages 551-561

  Briggs, Andrew H ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

Clinical trials; Cost effectiveness; Modelling; Uncertainty

Indexed keywords

HISTAMINE H2 RECEPTOR ANTAGONIST; PROKINETIC AGENT; PROTON PUMP INHIBITOR;

CLINICAL FEATURE; CLINICAL TRIAL; CONFIDENCE INTERVAL; COST EFFECTIVENESS ANALYSIS; DOSE RESPONSE; DYSPEPSIA; EVALUATION; GASTROENTEROLOGY; GASTROESOPHAGEAL REFLUX; HEALTH CARE COST; HEALTH ECONOMICS; HUMAN; MEDICAL DECISION MAKING; MEDICAL INFORMATION; MEDICAL PRACTICE; PATIENT CARE; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; RECURRENT DISEASE; REFLUX ESOPHAGITIS; REVIEW; STATISTICAL ANALYSIS; WOUND HEALING; COST BENEFIT ANALYSIS; ECONOMICS; HEALTH SERVICES RESEARCH; METHODOLOGY; STATISTICAL MODEL; UNCERTAINTY;

CONFIDENCE INTERVALS; COST-BENEFIT ANALYSIS; DATA INTERPRETATION, STATISTICAL; GASTROESOPHAGEAL REFLUX; HEALTH CARE COSTS; HEALTH SERVICES RESEARCH; HUMANS; MODELS, ECONOMETRIC; UNCERTAINTY;

EID: 2542614392     PISSN: 0954691X     EISSN: None     Source Type: Journal    
DOI: 10.1097/00042737-200406000-00007     Document Type: Review

References (29)

1. Delaney BC, Wilson S, Roalfe A, Roberts L, Redman V, Wearn A, et al. Cost-effectiveness of initial endoscopy for dyspepsia in patients over the age of 50 years: a randomised controlled trial in primary care. Lancet 2000; 356:1965-1969.
2. Briggs AH, Goeree R, Blackhouse G, O'Brien BJ. Probabilistic analysis of cost-effectiveness models: choosing between treatment strategies for gastroesophageal reflux disease. Med Decis Making 2002; 22:290-308.
3. Goeree R, O'Brien B, Hunt R, Blackhouse G, Willan A, Watson J. Economic evaluation of long-term management strategies for erosive oesophagitis. Pharmacoeconomics 1999; 16:679-697.
4. Black WC. The CE plane: a graphic representation of cost-effectiveness. Med Decis Making 1990; 10:212-214.
5. O'Brien BJ, Drummond MF, Labelle RJ, Willan A. In search of power and significance: issues in the design and analysis of stochastic cost-effectiveness studies in health care. Med Care 1994; 32:150-163.
6. Wakker P, Klaassen M. Confidence intervals for cost-effectiveness ratios. Health Economics 1995; 4:373-382.
7. Chaudhary MA, Stearns SC. Estimating confidence intervals for cost-effectiveness ratios: an example from a randomized trial. Statistics in Medicine 1996; 15:1447-1458.
8. Willan AR, O'Brien BJ. Confidence intervals for cost-effectiveness ratios: an application of Fieller's theorem. Health Economics 1996; 5:297-305.
9. Briggs AH, Wonderling DE, Mooney CZ. Pulling cost-effectiveness analysis up by its bootstraps: a non-parametric approach to confidence interval estimation. Health Economics 1997; 6:327-340.
10. Laheij RJ, Severens JL, Jansen JB. Empirical treatment or prompt endoscopy. Lancet 2001; 357:1366.
11. Gardner MJ, Altman DG. Estimation rather than hypothesis testing: confidence intervals rather than P values. In: Gardner MJ, Altman DG (editors). Statistics with Confidence. London: BMJ; 1989, pp. 6-19.
12. Briggs AH, O'Brien BJ. The death of cost-minimisation analysis? Health Economics 2001; 10:179-184.
13. Fieller EC. Some problems in interval estimation. J Royal Stat Soc, Series B 1954; 16:175-183.
14. Efron B, Tibshirani R. An Introduction to the Bootstrap. New York: Chapman & Hall; 1993.
15. van Hout B, Al MJ, Gordon GS, Rutten FF. Costs, effects and C/E-ratios alongside a clinical trial. Health Economics 1994; 3:309-319.
16. Polsky D, Glick HA, Willke R, Schulman K. Confidence intervals for cost-effectiveness ratios: a comparison of four methods. Health Economics 1997; 6:243-252.
17. Claxton K, Posnett J. An economic approach to clinical trial design and research priority-setting. Health Economics 1996; 5:513-524.
18. Tambour M, Zethraeus N, Johannesson M. A note on confidence intervals in cost-effectiveness analysis. Int J Technol Assess Health Care 1998; 14:467-471.
19. Stinnett AA, Mullahy J. Net health benefits: a new framework for the analysis of uncertainty in cost-effectiveness analysis. Med Decis Making 1998; 18 (2 suppl):S68-S80.
20. Claxton K. The irrelevance of inference: a decision-making approach to the stochastic evaluation of health care technologies. J Health Economics 1999; 18:341-364.
21. Lothgren M, Zethraeus N. Definition, interpretation and calculation of cost-effectiveness acceptability curves. Health Economics 2000; 9:623-630.
22. Doubilet P, Begg CB, Weinstein MC, Braun P, McNeil BJ. Probabilistic sensitivity analysis using Monte Carlo simulation. A practical approach. Med Decis Making 1985; 5:157-177.
23. Critchfield GC, Willard KE, Connelly DP. Probabilistic sensitivity analysis methods for general decision models. Computers Biomed Res 1986; 19:254-265.
24. Manning WG, Fryback DG, Weinstein MC. Reflecting uncertainty in cost-effectiveness analysis. In: Gold MR, Siegel JE, Russell LB, Weinstein MC (editors). Cost-effectiveness in Health and Medicine. New York: Oxford University Press; 1996, pp. 247-275.
25. Briggs AH. Handling uncertainty in cost-effectiveness models. Pharmacoeconomics 2000; 17:479-500.
26. Goeree R, O'Brien B, Hunt R, Blackhouse G, Willan A, Watson J. Economic evaluation of long-term management strategies for erosive oesophagitis. Pharmacoeconomics 1999; 16:679-697.
27. Gelman A, Carlin JB, Stern HS, Rubin DB. Bayesian Data Analysis. London: Chapman & Hall; 1995.
28. Cantor SB. Cost-effectiveness analysis, extended dominance, and ethics: a quantitative assessment. Med Decis Making 1994; 14:259-265.
29. Goeree R, O'Brien BJ, Blackhouse G, Marshall J, Briggs A, Lad R. Cost-effectiveness and cost-utility of long-term management strategies for heartburn. Value in Health 2002; 5:312-328.